OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter Formigenes
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced that, based on a positive opinion from the Paediatric Committee (PDCO), the European Medicines Agency (EMA) has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria. “We are pleased to […]
Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium
UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced it will be presenting a talk titled “Lantibiotics, a Novel Class of Antibiotics in the Pharmacopeia,” which will be part of a session dedicated to novel antimicrobial developments to counter multidrug-resistant bacterial infections […]
MRIdian System Limits Early Toxicity for Prostate Cancer Without Implanted Markers
UF startup ViewRay Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. This robust study of clinician and patient-reported outcomes […]
Ology Bioservices, Inc. Will Receive $9 Million of Funding to Support Manufacturing of Nipah Virus Vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide $43.6 million to advance the development and manufacture of the rVSV-Nipah vaccine candidate against the Nipah virus. UF startup Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), will receive $9M to support the manufacturing and stockpiling of the rVSV-Nipah vaccine. The Nipah virus, […]
Blue Water Vaccines, Developing Universal Flu Vaccine, to Partner With Ology Bioservices Inc.
Blue Water Vaccines, a Cincinnati-based biotechnology startup, has signed an agreement with UF startup Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), to manufacture a novel universal influenza vaccine. The vaccine, based on technology licensed from the prestigious University of Oxford in the U.K., has shown promising results in a preclinical study […]
Morphogenesis, Inc. Is Testing Cancer Vaccine
Scientists at UF startup Morphogenesis, Inc., a clinical-stage immunotherapy company headquartered in Tampa, call the “therapeutic vaccine” a simple and safe technology that could help people who already have cancer fight it off. Six patients with stage three and stage four melanoma started the trial in November 2018. Morphogenesis, Inc., is working with specialists at Moffitt […]
Virtual Humans Boost Mental Health Recovery
Benjamin Lok, a professor in the computer and information science and engineering department at the University of Florida, has been studying applications of virtual humans for two decades. His research has led to the creation of dozens of virtual characters that appear in 1,500 different programs around the world and wrack up over a million […]
Startup CEO Discusses Business Growth After Receiving Funding
UF startup Peerfit founder and CEO Ed Buckley gained a lot of traction with his business after receiving investment funding and coaching from organizations like Florida Funders. Peerfit promotes corporate wellness by giving the workforce access to exercise classes and programs through an interactive tech platform. The company grew from just four employees to more […]
Morphogenesis, Inc. Is Developing a Cell and Gene Therapy Focusing on a Cancer Vaccine Immunotherapy That Uses the Body’s Own Immune System to Kill Solid Tumors
Dr. Patricia Lawman, CEO and co-founder of UF startup Morphogenesis, Inc., a clinical-stage immunotherapy company headquartered in Tampa, talks about the company, their projects – current and future – and the challenges she and her team have to face while developing cell and gene therapy technologies. “We are currently focusing on our cancer vaccine. This […]
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, is pleased to report that its lead drugs for non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) Bemethyl (NP-135) and Bromantane (NP-160), exhibited highly statistically significant anti-fibrotic activity and outperformed known anti-fibrotic agents Telmisartan and Cenicriviroc. “We are planning off-label phase II clinical trials for […]